Using amide proton transfer to identify cervical squamous carcinoma/adenocarcinoma and evaluate its differentiation grade

Meng, Nan; Wang, Jing; Sun, Jiayuan; Liu, Wen-ling; Wang, Xuejia; Yan, Minghuan; Dwivedi, Akshay; Zheng, Dandan; Wang, Kaiyu; Han, Dongming

doi:10.1016/j.mri.2019.05.005

Cited by 18 publications

(15 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For clinical usage, the relationship between CEST values and traditional histology characteristics need to be studied more thoroughly. Several studies [ 52 , 60 ] have reported that MTR asym values were related to the histological grade or could differentiate the grades of tumors. However, only MTR asym values of Grade 3 (or moderate- to well-differentiated) lesions were significantly different from Grade 1 or 2 (poorly-differentiated) lesions.…”

Section: Discussion and Future Prospectsmentioning

confidence: 99%

See 1 more Smart Citation

A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging

Gao

Zou

et al. 2021

IJMS

View full text Add to dashboard Cite

Chemical exchange saturation transfer (CEST) MRI is a promising molecular imaging tool which allows the specific detection of metabolites that contain exchangeable amide, amine, and hydroxyl protons. Decades of development have progressed CEST imaging from an initial concept to a clinical imaging tool that is used to assess tumor metabolism. The first translation efforts involved brain imaging, but this has now progressed to imaging other body tissues. In this review, we summarize studies using CEST MRI to image a range of tumor types, including breast cancer, pelvic tumors, digestive tumors, and lung cancer. Approximately two thirds of the published studies involved breast or pelvic tumors which are sites that are less affected by body motion. Most studies conclude that CEST shows good potential for the differentiation of malignant from benign lesions with a number of reports now extending to compare different histological classifications along with the effects of anti-cancer treatments. Despite CEST being a unique ‘label-free’ approach with a higher sensitivity than MR spectroscopy, there are still some obstacles for implementing its clinical use. Future research is now focused on overcoming these challenges. Vigorous ongoing development and further clinical trials are expected to see CEST technology become more widely implemented as a mainstream imaging technology.

show abstract

Section: Discussion and Future Prospectsmentioning

confidence: 99%

“…Using a scanner from a different manufacturer than above studies, Meng et al [ 52 ] found that APT values in cervical cancer cases were higher than those of normal cervixes. The APT value of the cervical adenocarcinoma group was higher than that of the CSC group.…”

Section: Applicationsmentioning

confidence: 99%

A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging

Gao

Zou

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Hence, high cellularity contributes to increased APT signal. Nuclear atypia is another possible factor related to increased APT signals, owing to interactions with hydrophobic cell membranes and macromolecules [22][23][24]. Serous and clear cell carcinomas also exhibited higher APT max signals.…”

Section: Discussionmentioning

confidence: 99%

Amide proton transfer imaging in differentiation of type II and type I endometrial carcinoma: a pilot study

et al. 2021

View full text Add to dashboard Cite

Purpose This study aimed at evaluating the efficacy of amide proton transfer (APT) imaging in differentiation of type II and type I uterine endometrial carcinoma. Materials and methods Thirty-three patients diagnosed with uterine endometrial carcinoma, including 24 with type I and 9 with type II carcinomas, underwent APT imaging. Two readers evaluated the magnetization transfer ratio at 3.5 ppm [MTRasym (3.5 ppm)] in each type of carcinoma. The average MTRasym (APTmean) and the maximum MTRasym (APTmax) were analyzed. The receiver operating characteristic (ROC) curve analysis was performed. Results The APTmax was significantly higher in type II carcinomas than in type I carcinomas (reader1, p = 0.004; reader 2, p = 0.014; respectively). However, APTmean showed no significant difference between type I and II carcinomas. Based on the results reported by reader 1, the area under the curve (AUC) pertaining to the APTmax for distinguishing type I from type II carcinomas was 0.826, with a cut-off, sensitivity, and specificity of 9.90%, 66.7%, and 91.3%, respectively. Moreover, based on the results reported by reader 2, the AUC was 0.750, with a cut-off, sensitivity, and specificity of 9.80%, 62.5%, and 87.5%, respectively. Conclusion APT imaging has the potential to determine the type of endometrial cancer.

show abstract

“…For each parameter, the average value of the three ROIs was calculated, and the averages of values calculated by the two observers were recorded for further analysis. 26…”

Section: Discussionmentioning

confidence: 99%

“…In the same way, ROIs were drawn in the liver ~2 cm and 5 cm away from the tumor boundary to define the peritumoral tissue and normal liver parenchyma ROIs, respectively. For each parameter, the average value of the three ROIs was calculated, and the averages of values calculated by the two observers were recorded for further analysis 26 …”

Section: Methodsmentioning

confidence: 99%

Prediction Model for Intermediate‐Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization

Jia

Yan

et al. 2020

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

Background: The outcome of intermediate-stage hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) is greatly heterogeneous. Current means for predicting HCC response to TACE are lacking. Purpose: To investigate whether the combination of parameters derived from amide proton transfer (APT) and intravoxel incoherent motion (IVIM) imaging, and morphological characteristics of tumor can establish a better prediction model than the univariant model for HCC response to TACE. Study Type: Prospective. Subjects: 56 patients with intermediate-stage HCC (50 males and six females). Field Strength/Sequences: 3.0T; T 2-weighted-fast spin echo, 3D liver acquisition with volume flex, single-shot fast spin echo-planar imaging (EPI), spin echo-EPI. Assessment: Pretreatment APT signal intensities (SIs), apparent diffusion coefficient (ADC), true molecular diffusion coefficient (D), pseudodiffusion coefficient (D*), and perfusion fraction (f) for tumor, peritumoral, and normal tissues were measured. Follow-up MRI scanning was performed, and the patients were classified as responders or nonresponders based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Statistical Tests: The imaging parameters were compared among the three tissues and between the two groups using analysis of variance (ANOVA) or two-sample t-test. The prediction model's variables were derived from univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve analysis was used to explore the predictive performance. Results: Based on the logistic regression analysis results, we established a prediction model that integrated the APT SI and D values in the tumor tissue and the tumor size. ROC analyses revealed that the model was better able to predict tumor response to TACE (area under the ROC curve = 0.851) than the individual parameters on their own. Data Conclusion: A prediction model incorporating pretreatment APT SI, D in the tumor tissue and tumor size may be useful for predicting the response of intermediate-stage HCC to TACE. Level of Evidence: 1 Technical Efficacy: Stage 1

show abstract

Using amide proton transfer to identify cervical squamous carcinoma/adenocarcinoma and evaluate its differentiation grade

Cited by 18 publications

References 32 publications

A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging

A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging

Amide proton transfer imaging in differentiation of type II and type I endometrial carcinoma: a pilot study

Prediction Model for Intermediate‐Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization

Contact Info

Product

Resources

About